Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil

Introduction Solid organ transplant (SOT) recipients are at increased risk of Human Papillomavirus (HPV) persistent infection and disease. This study aimed to evaluate HPV seroprevalence, cervical HPV prevalence, genotype distribution, and frequency of HPV-related cervical lesions in SOT recipients in comparison to immunocompetent women. Methods Cross-sectional study including SOT and immunocompetent women aged 18 to 45 years who denied previous HPV-related lesions. Cervical samples were screened for HPV-DNA by a polymerase chain reaction (PCR)-based DNA microarray system (PapilloCheck (R)) and squamous intraepithelial lesions (SIL) by liquid-based cytology. A multiplexed pseudovirion-based serology assay (PsV-Luminex) was used to measure HPV serum antibodies. Results 125 SOT and 132 immunocompetent women were enrolled. Cervical samples were collected from 113 SOT and 127 immunocompetent women who had initiated sexual activity. HPV-DNA prevalence was higher in SOT than in immunocompetent women (29.6% vs. 20.2%, p = 0.112), but this difference was not statistically significant. High-risk (HR)-HPV was significantly more frequent in SOT than in immunocompetent women (19.4% vs. 7.9%, p = 0.014). Simultaneous infection with >= 2 HR-HPV types was found in 3.1% of SOT and 0.9% of immunocompetent women. HPV seropositivity for at least one HPV type was high in both groups: 63.8% of 105 SOT and 69.7% of 119 immunocompetent women (p = 0.524). Low-grade (LSIL) and high-grade SIL (HSIL) were significantly more frequent in SOT (9.7% and 5.3%, respectively) than in immunocompetent women (1.6% and 0.8%, respectively) (p= 0.001). Conclusions These results may reflect the increased risk of HPV persistent infection and disease progression in SOT women due to chronic immunosuppression.

URI

https://observatorio.fm.usp.br/handle/OPI/48425

Referências

Bruni L, 2019, HUMAN PAPILLOMAVIRUS
Colpani V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229154
Dugue PA, 2013, EXPERT REV ANTICANC, V13, P29, DOI [10.1586/ERA.12.159, 10.1586/era.12.159]
Eleuterio J, 2019, DIAGN CYTOPATHOL, V47, P783, DOI 10.1002/dc.24180
Faust H, 2013, J CLIN VIROL, V56, P336, DOI 10.1016/j.jcv.2012.12.004
Instituto Nacioanl do Cancer Ministerio da Saude, 2020, CONTR CANC COL UT
Kellerman L, 2009, AM J CARDIOL, V103, P562, DOI 10.1016/j.amjcard.2008.10.026
Kessler M, 2006, TRANSPL INT, V19, P908, DOI 10.1111/j.1432-2277.2006.00383.x
Kumar D, 2013, AM J TRANSPLANT, V13, P2411, DOI 10.1111/ajt.12329
Mazanowska N, 2013, ANN TRANSPL, V18, P656, DOI 10.12659/AOT.884029
MInisterio da Saude Instituto Nacional do Cancer, 2016, DIR BRAS RASTR CANC, V2
Nayar R., 2015, BETHESDA SYSTEM REPO, DOI [10.1007/978-3-319-11074-5, DOI 10.1007/978-3-319-11074-5]
Nicol AF, 2013, J CLIN VIROL, V57, P147, DOI 10.1016/j.jcv.2013.02.007
Paulino E, 2020, JCO GLOB ONCOL, V6, P1617, DOI 10.1200/GO.20.00099
Rama Cristina Helena, 2006, Rev. Assoc. Med. Bras., V52, P43, DOI 10.1590/S0104-42302006000100021
Rama CH, 2010, INT J GYNECOL CANCER, V20, P1405, DOI 10.1111/IGC.0b013e3181f3c85e
Registro Brasileiro de Transplantes-Veiculo Oficial da Associacao Brasileira de Transplante de Orgaos, 2019, DIM TRANSPL BRAS CAD
Reinholdt K, 2020, INT J CANCER, V146, P2413, DOI 10.1002/ijc.32565
Roensbo MT, 2018, ACTA OBSTET GYN SCAN, V97, P142, DOI 10.1111/aogs.13261
Suwalska A, 2020, TRANSPL P, V52, P1982, DOI 10.1016/j.transproceed.2020.03.032
World Health Organization, HLTH TOP CERV CANC

Coleções

Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/48
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - LIM/60
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo